GSK's Wellcovorin Wins FDA Approval as First Therapy for Cerebral Folate Deficiency

Patients with cerebral folate deficiency, a rare genetic disorder affecting brain function, now have access to the first approved treatment option.

For families navigating a diagnosis without a treatment, medicine has long offered a particular kind of cruelty — the name of a condition without a path forward. On Tuesday, the FDA approved GSK's Wellcovorin as the first sanctioned therapy for cerebral folate deficiency, a rare genetic disorder in which the brain is starved of folate due to a faulty transport mechanism. The approval does not merely add a drug to a formulary; it closes a gap between diagnosis and hope for a small but profoundly affected population, and signals that even the rarest of conditions can earn the attention of scienc

GSK's Wellcovorin Wins FDA Approval as First Therapy for Cerebral Folate Deficiency

Cobertura Relacionada

Receba o Register no seu e-mail